Weisman A, et al. – Researchers conducted a population-based retrospective cohort study in Ontario, Canada to evaluate the connection between allopurinol, mortality, and cardiovascular outcomes in an allopurinol-treated diabetes cohort. They assessed patients aged ≥ 66 years with diabetes and a first prescription for allopurinol between April 1, 2002-March 31, 2012, who were followed until March 31, 2016. An association was found between allopurinol and reduced mortality and cardiovascular outcomes. Lack of cumulative dose effect and a positive tracer outcome in males, however, suggested residual bias.